Multiple myeloma: An update

Khalil Al-Farsi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Citations (Scopus)


Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients usually present with hypercalcemia, renal insufciency, anemia and/or lytic bony lesions along with a monoclonal protein in the serum and/or urine in addition to an increase in the number of clonal plasma cells in the bone marrow. Patients with myeloma live on an average for fve to seven years, with their survival dependent on the presence or absence of diferent prognostic markers. Treatment of younger ft patients is with induction therapy consisting of steroids with one or more novel anti-myeloma agents followed by high dose melphalan and autologous stem cell transplantation, while older and less ft patients are treated with melphalan-based combination chemotherapy. Supportive care is of paramount importance and includes the use of bisphosphonates, prophylactic antibiotics, thrombosis prophylaxis and the use of hematopoietic growth factors along with the treatment of complications of disease and its therapy. As more progress is being made and deeper responses are being attained, the disease might turn into a potentially curable one in the near future.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalOman Medical Journal
Issue number1
Publication statusPublished - 2013


  • Monoclonal gammopathy
  • Multiple myeloma
  • Myeloma
  • Plasma cell dyscrasia
  • Plasma cell myeloma

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Multiple myeloma: An update'. Together they form a unique fingerprint.

Cite this